BCL2 and B-cell chronic lymphocytic leukemia: GSK-3ß has been shown to accumulate in the nucleus of B-CLL cells, and its inhibition has been associated with epigenetic changes in the promoters of the antiapoptotic genes BCL2 and XIAP, which preclude p65 from binding to them [8].